tbuckley/cabot-search huggingface dataset:
Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma
Authors: Owen S. Chapman, Jens Luebeck, Sunita Sridhar, Ivy Tsz-Lo Wong, Deobrat Dixit, Shanqing Wang, Gino Prasad, Utkrisht Rajkumar, Meghana S. Pagadala, Jon D. Larson, Britney Jiayu He, King L. Hung, Joshua T. Lange, Siavash R. Dehkordi, Sahaana Chandran, Miriam Adam, Ling Morgan, Sameena Wani, Ashutosh Tiwari, Caitlin Guccione, Yingxi Lin, Aditi Dutta, Yan Yuen Lo, Edwin Juarez, James T. Robinson, Andrey Korshunov, John-Edward A. Michaels, Yoon-Jae Cho, Denise M. Malicki, Nicole G. Coufal, Michael L. Levy, Charlotte Hobbs, Richard H. Scheuermann, John R. Crawford, Scott L. Pomeroy, Jeremy N. Rich, Xinlian Zhang, Howard Y. Chang, Jesse R. Dixon, Anindya Bagchi, Aniruddha J. Deshpande, Hannah Carter, Ernest Fraenkel, Paul S. Mischel, Robert J. Wechsler-Reya, Vineet Bafna, Jill P. Mesirov, Lukas Chavez
Journal: Nature Genetics (2023)

Circular extrachromosomal DNA (ecDNA) in patient tumors is an important driver of oncogenic gene expression, evolution of drug resistance and poor patient outcomes. Applying computational methods for the detection and reconstruction of ecDNA across a retrospective cohort of 481 medulloblastoma tumors from 465 patients, we identify circular ecDNA in 82 patients (18%). Patients with ecDNA-positive medulloblastoma were more than twice as likely to relapse and three times as likely to die within 5 years of diagnosis. A subset of tumors harbored multiple ecDNA lineages, each containing distinct amplified oncogenes. Multimodal sequencing, imaging and CRISPR inhibition experiments in medulloblastoma models reveal intratumoral heterogeneity of ecDNA copy number per cell and frequent putative 'enhancer rewiring' events on ecDNA. This study reveals the frequency and diversity of ecDNA in medulloblastoma, stratified into molecular subgroups, and suggests copy number heterogeneity and enhancer rewiring as oncogenic features of ecDNA.
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
Authors: Arkadiusz Liskiewicz, Ahmed Khalil, Daniela Liskiewicz, Aaron Novikoff, Gerald Grandl, Gandhari Maity-Kumar, Robert M. Gutgesell, Mostafa Bakhti, Aimée Bastidas-Ponce, Oliver Czarnecki, Konstantinos Makris, Heiko Lickert, Annette Feuchtinger, Monica Tost, Callum Coupland, Lisa Ständer, Seun Akindehin, Sneha Prakash, Faiyaz Abrar, Russell L. Castelino, Yantao He, Patrick J. Knerr, Bin Yang, Wouter F. J. Hogendorf, Shiqi Zhang, Susanna M. Hofmann, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, Jonathan D. Douros, Timo D. Müller
Journal: Nature Metabolism (2023)

Abstract The development of single-molecule co-agonists for the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) is considered a breakthrough in the treatment of obesity and type 2 diabetes. But although GIPR–GLP-1R co-agonism decreases body weight with superior efficacy relative to GLP-1R agonism alone in preclinical 1–3 and clinical studies 4,5 , the role of GIP in regulating energy metabolism remains enigmatic. Increasing evidence suggests that long-acting GIPR agonists act in the brain to decrease body weight through the inhibition of food intake 3,6–8 ; however, the mechanisms and neuronal populations through which GIP affects metabolism remain to be identified. Here, we report that long-acting GIPR agonists and GIPR–GLP-1R co-agonists decrease body weight and food intake via inhibitory GABAergic neurons. We show that acyl-GIP decreases body weight and food intake in male diet-induced obese wild-type mice, but not in mice with deletion of Gipr in Vgat (also known as Slc32a1 )-expressing GABAergic neurons ( Vgat-Gipr knockout). Whereas the GIPR–GLP-1R co-agonist MAR709 leads, in male diet-induced obese wild-type mice, to greater weight loss and further inhibition of food intake relative to a pharmacokinetically matched acyl-GLP-1 control, this superiority over GLP-1 vanishes in Vgat-Gipr knockout mice. Our data demonstrate that long-acting GIPR agonists crucially depend on GIPR signaling in inhibitory GABAergic neurons to decrease body weight and food intake.
Transcriptionally defined amygdala subpopulations play distinct roles in innate social behaviors
Authors: Julieta E. Lischinsky, Luping Yin, Chenxi Shi, Nandkishore Prakash, Jared Burke, Govind Shekaran, Maria Grba, Joshua G. Corbin, Dayu Lin
Journal: Nature Neuroscience (2023)

Social behaviors are innate and supported by dedicated neural circuits, but the molecular identities of these circuits and how they are established developmentally and shaped by experience remain unclear. Here we show that medial amygdala (MeA) cells originating from two embryonically parcellated developmental lineages have distinct response patterns and functions in social behavior in male mice. MeA cells expressing the transcription factor Foxp2 (MeA
Asthma and incident coronary heart disease: an observational and Mendelian randomisation study
Authors: Carlos A. Valencia-Hernández, Fabiola Del Greco M, Varun Sundaram, Laura Portas, Cosetta Minelli, Chloe I. Bloom
Journal: European Respiratory Journal (2023)

Background Observational studies suggest asthma is a risk factor for coronary heart disease (CHD) and sex modifies the risk, but they may suffer from methodological limitations. To overcome these, we applied a “triangulation approach”, where different methodologies, with different potential biases, were leveraged to enhance confidence in findings. Methods First, we conducted an observational study using UK medical records to match asthma patients 1:1, by age, sex and general practitioner (GP) practice, to the general population. We measured the association between asthma and incident CHD (myocardial infarction: hospitalisation/death) by applying minimal sufficient adjustment: model 1, smoking, body mass index, oral corticosteroids, atopy and deprivation; model 2, additionally adjusting for healthcare behaviour (GP consultation frequency). Second, we conducted a Mendelian randomisation (MR) study using data from the UK Biobank, Trans-National Asthma Genetic Consortium (TAGC) and Coronary Artery Disease Genome-wide Replication and Meta-analysis consortium (CARDIoGRAM). Using 64 asthma single nucleotide polymorphisms, the effect of asthma on CHD was estimated with inverse variance-weighted meta-analysis and methods that adjust for pleiotropy. Results In our observational study (n=1 522 910), we found asthma was associated with 6% increased risk of CHD (model 1: HR 1.06, 95% CI 1.01–1.13); after accounting for healthcare behaviour, we found no association (model 2: HR 0.99, 95% CI 0.94–1.05). Asthma severity did not modify the association, but sex did (females: HR 1.11, 95% CI 1.01–1.21; males: HR 0.91, 95% CI 0.84–0.98). Our MR study (n=589 875) found no association between asthma and CHD (OR 1.01, 95% CI 0.98–1.04) and no modification by sex. Conclusions Our findings suggest that asthma is not a risk factor for CHD. Previous studies may have suffered from detection bias or residual confounding.
Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing
Authors: Jay Achar, James A. Seddon, Gwenan M. Knight, Peter J. Dodd, Hanif Esmail, Jennifer Hughes, C. Finn McQuaid
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>Second-line drug susceptibility test results are frequently unavailable for people with TB. A method is proposed for comparing risks and benefits of different treatment regimens for rifampicin-resistant TB when accurate results are unavailable.</b> https://bit.ly/46KHyl0
Best step-up treatments for children with uncontrolled asthma: a systematic review and network meta-analysis of individual participant data
Authors: Sofia Cividini, Ian Sinha, Sarah Donegan, Michelle Maden, Katie Rose, Olivia Fulton, Giovanna Culeddu, Dyfrig A. Hughes, Stephen Turner, Catrin Tudur Smith
Journal: European Respiratory Journal (2023)

Background There is uncertainty about the best treatment option for children/adolescents with uncontrolled asthma despite inhaled corticosteroids (ICS) and international guidelines make different recommendations. We evaluated the pharmacological treatments to reduce asthma exacerbations and symptoms in uncontrolled patients age &lt;18 years on ICS. Methods We searched MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Embase, Web of Science, National Institute for Health and Care Excellence Technology Appraisals, National Institute for Health and Care Research Health Technology Assessment series, World Health Organization International Clinical Trials Registry, conference abstracts and internal clinical trial registers (1 July 2014 to 5 May 2023) for randomised controlled trials of participants age &lt;18 years with uncontrolled asthma on any ICS dose alone at screening. Studies before July 2014 were retrieved from previous systematic reviews/contact with authors. Patients had to be randomised to any dose of ICS alone or combined with long-acting β 2 -agonists (LABA) or combined with leukotriene receptor antagonists (LTRA), LTRA alone, theophylline or placebo. Primary outcomes were exacerbation and asthma control. The interventions evaluated were ICS (low/medium/high dose), ICS+LABA, ICS+LTRA, LTRA alone, theophylline and placebo. Results Of the 4708 publications identified, 144 trials were eligible. Individual participant data were obtained from 29 trials and aggregate data were obtained from 19 trials. Compared with ICS Low, ICS Medium+LABA was associated with the lowest odds of exacerbation (OR 0.44, 95% credibility interval (95% CrI) 0.19–0.90) and with an increased forced expiratory volume in 1 s (mean difference 0.71, 95% CrI 0.35–1.06). Treatment with LTRA was the least preferred. No apparent differences were found for asthma control. Conclusions Uncontrolled children/adolescents on low-dose ICS should be recommended a change to medium-dose ICS+LABA to reduce the risk for exacerbation and improve lung function.
World Pneumonia Day 2023: the rising global threat of pneumonia and what we must do about it
Authors: Catia Cilloniz, Charles Dela Cruz, Walter H. Curioso, Cesar Herrera Vidal
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>On 12 November 2023 we mark World Pneumonia Day. The day is an opportunity to raise awareness, advocate for and give visibility to pneumonia, the leading infectious cause of death across all age groups globally</b>https://bit.ly/3QjSJuf
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one<i>F508del</i>allele: 144-week interim results from a 192-week open-label extension study
Authors: Cori L. Daines, Elizabeth Tullis, Stefano Costa, Rachel W. Linnemann, Marcus A. Mall, Edward F. McKone, Deepika Polineni, Bradley S. Quon, Felix C. Ringshausen, Steven M. Rowe, Hiran Selvadurai, Jennifer L. Taylor-Cousar, Nicholas J. Withers, Neil Ahluwalia, Samuel M. Moskowitz, Valentin Prieto-Centurion, Yaoyuan Vincent Tan, Simon Tian, Tanya Weinstock, Fengjuan Xuan, Yaohua Zhang, Bonnie Ramsey, Matthias Griese
Journal: European Respiratory Journal (2023)

Background In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) ≥12 years of age who have at least one F508del allele. The aim of this study is to assess long-term safety and efficacy of ELX/TEZ/IVA in these patients. Methods In this phase 3, open-label, single-arm extension study, participants with F508del –minimal function (from a 24-week parent study; n=399) or F508del – F508del (from a 4-week parent study; n=107) genotypes receive ELX/TEZ/IVA at the same dose (ELX 200 mg once daily, TEZ 100 mg once daily and IVA 150 mg every 12 h). The primary end-point is safety and tolerability. A prespecified interim analysis was conducted when the last participant reached the Week 144 visit. Results At the Week 144 interim analysis, mean duration of exposure to ELX/TEZ/IVA in the extension study was 151.1 weeks. Exposure-adjusted rates of adverse events (AEs) (586.6 events per 100 participant-years) and serious AEs (22.4 events per 100 participant-years) were lower than in the ELX/TEZ/IVA treatment group in the 24-week parent study (1096.0 and 36.9 events per 100 participant-years, respectively); most participants had AEs classified as mild (16.4% of participants) or moderate (60.3% of participants) in severity. 14 participants (2.8%) had AEs that led to treatment discontinuation. Following initiation of ELX/TEZ/IVA, participants had increases in forced expiratory volume in 1 s (FEV 1 ) percentage predicted, Cystic Fibrosis Questionnaire-Revised respiratory domain score and body mass index, and had decreases in sweat chloride concentration and pulmonary exacerbation rates that were maintained over the interim analysis period. The mean annualised rate of change in FEV 1 % pred was +0.07 (95% CI −0.12–0.26) percentage points among the participants. Conclusions ELX/TEZ/IVA was generally safe and well tolerated, with a safety profile consistent with the 24-week parent study. Participants had sustained improvements in lung function, respiratory symptoms, CF transmembrane conductance regulator function, pulmonary exacerbation rates and nutritional status. These results support the favourable safety profile and durable, disease-modifying clinical benefits of ELX/TEZ/IVA.
Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis
Authors: Rubeshan Perumal, Neda Bionghi, Camus Nimmo, Marothi Letsoalo, Matthew J. Cummings, Madeleine Hopson, Allison Wolf, Shamim Al Jubaer, Nesri Padayatchi, Kogieleum Naidoo, Michelle H. Larsen, Max O'Donnell
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>Bedaquiline resistance is a major threat to drug-resistant tuberculosis control strategies. This analysis found a pooled prevalence of baseline bedaquiline resistance of 2.4% and a pooled prevalence of treatment-emergent bedaquiline resistance of 2.1%.</b> https://bit.ly/3FC6yio
Removal or ablation of asymptomatic lung metastases should be reconsidered
Authors: Fergus Macbeth, Lesley Fallowfield, Elizabeth Treasure, Irfan Ahmad, Yan Zheng, Tom Treasure
Journal: BMJ (2023)

Fergus Macbeth and Tom Treasure, as an oncologist and a surgeon treating cancer have lifelong clinical experience in the NHS.They have each led cancer trials including PulMiCC, worked with NICE and Cochrane, and have collaborated in disseminating evidence-based knowledge.Lesley Fallowfield is an academic psycho-oncologist involved in health outcomes research, research methods and cancer education, and co-chief investigator of the PulMiCC trial.Elizabeth Treasure is a breast cancer survivor
How does medicine assess AI?
Authors: Chris Stokel-Walker
Journal: BMJ (2023)

Artificial intelligence is touted as saving time and improving accuracy of diagnosis, among other benefits in medicine. How are such claims being evaluated? Chris Stokel-Walker reports Mindaugas Galvosas, a doctor in Switzerland, is excited. “Personally, I am extremely excited for what’s ahead for the field of acoustic epidemiology, and I have no doubt that cough counting will be as mainstream as step counting is—or even as thermometry is.” He’s talking about a cough monitoring app, Hyfe, that is powered by artificial intelligence and that its manufacturer says will be able to use a patient’s pattern of coughing to diagnose disease. “Machine learning allowed for automating cough monitoring, with the new technologies being able to run in the background of any device with a mic and timestamp coughs as they happen to a millisecond,” says Galvosas, medical officer for Hyfe. Hyfe is one of many AI powered tools claiming to supercharge medicine, saving time and labour for overstretched medical staff. Mention of generative AI (box 1) has become inescapable in the year since the research firm OpenAI released ChatGPT to the world in November 2022. Every week it seems like a new tool promising to aid doctors is released by big and small companies alike. In July 2023, for instance, Google claimed that one of its AI systems was more effective than doctors at analysing medical scans, while also reducing doctors’ workload by 66%.1 Box 1 ### What is generative AI? Generative AI is a collective term for chatbot-style tools that can create text, including prose, poetry, or computer code, on demand, often through use of a simple “chat box” window. Their ease of use by experts and non-experts alike, and the seemingly fluent output—much of which can fool most readers into thinking the author was human—has led to widespread adoption by companies and the public. Such … RETURN TO TEXT
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative
Authors: Alexander G. S. Oldroyd, Jeffrey P. Callen, Hector Chinoy, Lorinda Chung, David Fiorentino, Patrick Gordon, Pedro M. Machado, Neil McHugh, Albert Selva-O’Callaghan, Jens Schmidt, Sarah L. Tansley, Ruth Ann Vleugels, Victoria P. Werth, Anthony A. Amato, Helena Andersson, Lilia Andrade-Ortega, Dana Ascherman, Olivier Benveniste, Lorenzo Cavagna, Christina Charles-Shoeman, Benjamin F. Chong, Lisa Christopher-Stine, Jennie T. Clarke, Emma J. Crosbie, Philip A. J. Crosbie, Sonye Danoff, Maryam Dastmalchi, Marianne De Visser, Paul F. Dellaripa, Louise Pyndt Diederichsen, Mazen M. Dimachkie, Erik Ensrud, Floranne Ernste, D. Gareth R. Evans, Manabu Fujimoto, Ignacio Garcia-De La Torre, Abraham Garcia-Kutzbach, Zoltan Griger, Latika Gupta, Marie Hudson, Florenzo Iannone, David Isenberg, Joseph Jorizzo, Helen Kurtz, Masataka Kuwana, Vidya Limaye, Ingrid E. Lundberg, Andrew L. Mammen, Herman Mann, Frank Mastaglia, Lorna McWilliams, Christopher A. Mecoli, Federica Meloni, Frederick W. Miller, Siamak Moghadam-Kia, Sergey Moiseev, Yoshinao Muro, Melinda Nagy-Vincze, Clive Nayler, Merrilee Needham, Ichizo Nishino, Chester V. Oddis, Julie J. Paik, Joost Raaphorst, Lisa G. Rider, Jorge Rojas-Serrano, Lesley Ann Saketkoo, Adam Schiffenbauer, Samuel Katsuyuki Shinjo, Vineeta Shobha, Yeong-Wook Song, Tania Tillett, Yves Troyanov, Anneke J. van der Kooi, Mónica Vázquez-Del Mercado, Jiri Vencovsky, Qian Wang, Steven Ytterberg, Rohit Aggarwal
Journal: Nature Reviews Rheumatology (2023)
Anticoagulation and Bleeding during Veno-Venous Extracorporeal Membrane Oxygenation: Insights from the PROTECMO Study
Authors: Gennaro Martucci, Marco Giani, Matthieu Schmidt, Kenichi Tanaka, Ali Tabatabai, Fabio Tuzzolino, Cara Agerstrand, Jordi Riera, Raj Ramanan, Giacomo Grasselli, Ali Ait Hssain, Whitney D. Gannon, Sara Buabbas, Vojka Gorjup, Brian Trethowan, Monica Rizzo, Vito Fanelli, Kyeongman Jeon, Gennaro De Pascale, Alain Combes, Marco V. Ranieri, Thibault Duburcq, Giuseppe Foti, Juan I. Chico, Martin Balik, Lars Mikael Broman, Peter Schellongowski, Hergen Buscher, Roberto Lorusso, Daniel Brodie, Antonio Arcadipane, Matteo Brioni, Antonio Pesenti, Luca Montini, Linda Bosa, Luca Brazzi, Pierfrancesco Curcio, Eugenio Garofalo, Luis Martin-Villen, Raquel Garcìa-Álvarez, Marta Lopez Sanchez, Nuno Principe, Violeta Chica Saez, Santiago Freita, Joaquin Colomina-Climent, Andres F. Pacheco, Julien Goutay, Konstanty Szułdrzyński, Mariusz Kowalewski, Philipp Eller, Elisabeth Lobmeyr, Silvia Mariani, Pavel Suk, Michal Maly, Jakob Forestier, Nicolò Rizzitello, Marco Barbara, Tyler Holsworth, Alexis Serra, Yiorgos A. Cavayas, Jay Menaker, Samuel Galvagno, Todd W. Rice, Wilson E. Grandin, Jose Nunez, Collette Cheplic, Harikesh Subramanian, Ryan Rivosecchi, Young-Jae Cho, Ming Chit Kwan, Hend Sallam, Joy A. Villanueva, Jeffrey Aliudin, Kota Hoshino, Yoshitaka Hara, Kollengode Ramanathan, Graeme Maclaren, Hergen Buscher
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Definitive guidelines for anticoagulation management during veno-venous extracorporeal membrane oxygenation (VV ECMO) are lacking, whereas bleeding complications continue to pose major challenges.
Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care Personnel — National Healthcare Safety Network, United States, 2022–23 Influenza Season
Authors: Jeneita Bell, Lu Meng, Kira Barbre, Emily Haanschoten, Hannah E. Reses, Minn Soe, Jonathan Edwards, Jason Massey, Gnanendra Reddy Tugu Yagama Reddy, Austin Woods, Matthew J. Stuckey, David T. Kuhar, Kayla Bolden, Heather Dubendris, Emily Wong, Theresa Rowe, Megan C. Lindley, Elizabeth J. Kalayil, Andrea Benin
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

The Advisory Committee on Immunization Practices recommends that health care personnel (HCP) receive an annual influenza vaccine and that everyone aged ≥6 months stay up to date with recommended COVID-19 vaccination. Health care facilities report vaccination of HCP against influenza and COVID-19 to CDC's National Healthcare Safety Network (NHSN). During January-June 2023, NHSN defined up-to-date COVID-19 vaccination as receipt of a bivalent COVID-19 mRNA vaccine dose or completion of a primary series within the preceding 2 months. This analysis describes influenza and up-to-date COVID-19 vaccination coverage among HCP working in acute care hospitals and nursing homes during the 2022-23 influenza season (October 1, 2022-March 31, 2023). Influenza vaccination coverage was 81.0% among HCP at acute care hospitals and 47.1% among those working at nursing homes. Up-to-date COVID-19 vaccination coverage was 17.2% among HCP working at acute care hospitals and 22.8% among those working at nursing homes. There is a need to promote evidence-based strategies to improve vaccination coverage among HCP. Tailored strategies might also be useful to reach all HCP with recommended vaccines and protect them and their patients from vaccine-preventable respiratory diseases.
Arthritis Prevalence Among Veterans — United States, 2017–2021
Authors: Elizabeth A. Fallon, Michael A. Boring, Anika L. Foster, Ellen W. Stowe, Tyler D. Lites, Kelli D. Allen
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Arthritis is a chronic inflammatory condition and a leading cause of chronic pain and disability. Because arthritis prevalence is higher among U.S. military veterans (veterans), and because the veteran population has become more sexually, racially, ethnically, and geographically diverse, updated arthritis prevalence estimates are needed. CDC analyzed pooled 2017-2021 Behavioral Risk Factor Surveillance System data to estimate the prevalence of diagnosed arthritis among veterans and nonveterans, stratified by sex and selected demographic characteristics. Approximately one third of veterans had diagnosed arthritis (unadjusted prevalence = 34.7% [men] and 31.9% [women]). Among men aged 18-44 years, arthritis prevalence among veterans was double that of nonveterans (prevalence ratio [PR] = 2.1; 95% CI = 1.9-2.2), and among men aged 45-64 years, arthritis prevalence among veterans was 30% higher than that among nonveterans (PR = 1.3; 95% CI = 1.3-1.4). Among women aged 18-44 years, arthritis prevalence among veterans was 60% higher than that among nonveterans (PR = 1.6; 95% CI = 1.4-1.7); among women aged 45-64 years, arthritis prevalence among veterans was 20% higher than that among nonveterans (PR = 1.2; 95% CI = 1.1-1.3). Cultivating partnerships with veteran-serving organizations to promote or deliver arthritis-appropriate interventions might be advantageous, especially for states where arthritis prevalence among veterans is highest. The high prevalence of arthritis among female veterans, veterans aged ≥65 years, and veterans with disabilities highlights the importance of ensuring equitable access and inclusion when offering arthritis-appropriate interventions.